Inhibitory effects of ketotifen on eotaxin-dependent activation of eosinophils: Consequences for allergic eye diseases

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 58, Issue 5, 2003, Pages 397-406

  Woerly, G ^a   Loiseau, S ^a   Loyens, M ^a   Schoch, C ^b   Capron, Monique ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Chemiluminescence; Chemotaxis; Conjunctivitis; Degranulation; Eosinophils; Eotaxin; Interleukin 5; Ketotifen

Indexed keywords

EOSINOPHIL CATIONIC PROTEIN; EOSINOPHIL PROTEIN X; EOTAXIN; FORMYLMETHIONYLLEUCYLPHENYLALANINE; IMMUNOGLOBULIN A; INTERLEUKIN 5; KETOTIFEN;

ALLERGY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BOYDEN CHAMBER; CELL SEPARATION; CHEMOLUMINESCENCE; CHEMOTAXIS; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; EOSINOPHIL; EYE DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPEREOSINOPHILIA; IMMUNOGLOBULIN PRODUCTION; INHIBITION KINETICS; MAGNETIC CELL SEPARATION; MEDIATOR RELEASE; OXIDATION KINETICS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PURIFICATION; RADIOIMMUNOASSAY; STATISTICAL SIGNIFICANCE;

ANTI-ALLERGIC AGENTS; BLOOD PROTEINS; CASE-CONTROL STUDIES; CELL SURVIVAL; CHEMOKINES, CC; CHEMOTACTIC FACTORS, EOSINOPHIL; CHEMOTAXIS, LEUKOCYTE; DOSE-RESPONSE RELATIONSHIP, DRUG; EOSINOPHIL-DERIVED NEUROTOXIN; EOSINOPHILS; EYE DISEASES; HUMANS; INTERLEUKIN-5; KETOTIFEN; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; OXIDATION-REDUCTION; REACTIVE OXYGEN SPECIES; RIBONUCLEASES;

EID: 0037852134     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1398-9995.2003.00081.x     Document Type: Article

References (52)

1. MCGILL JI, HOLGATE ST, CHURCH MK, ANDERSON DF, BACON A. Allergic eye disease mechanisms. Br J Ophthalmol 1998;82:1203-1214.
2. BONINI S, MAGRINI L, ROTIROTI G, LAMBIASE A, TOMASSINI M, RUMI C. The eosinophil and the eye. Allergy 1997;52:44-47.
3. TROCME SD, KEPHART GM, ALLANSMITH MR, BOURNE WM, GLEICH GJ. Conjunctival deposition of eosinophil granule major basic protein in vernal keratoconjunctivitis and contact lens-associated giant papillary conjunctivitis. Am J Ophthalmol 1989;108:57-63.
4. TROCME SD, GLEICH GJ, KEPHART GM, ZIESKE JD. Eosinophil granule major basic protein inhibition of corneal epithelial wound healing. Invest Ophthalmol Vis Sci 1994;35:3051-3056.
5. DESREUMAUX P, CAPRON M. Eosinophils in allergic reactions. Curr Opin Immunol 1996;8:790-795.
6. CAPRON M, LOISEAU S, PAPIN JP, ROBERTSON S, CAPRON A. Inhibitory effects of lodoxamide on eosinophil activation. Int Arch Allergy Immunol 1998;116:140-146.
7. ROTIROTI G, ONORATI P. IL-5 in tears of vernal keratoconjunctivitis patients. Allergy 1995;50:180.
8. NORDERHAUG IN, SCHJERVEN JJ, BRANDTZAEG P. Regulation of the formation and external transport of secretory immunoglobulins. Criti Rev Immunol 1999;19:481-508.
9. TOMASSINI M, TSICOPOULOS A, TAI PC et al. Release of granule proteins by eosinophils from allergic and nonallergic patients with eosinophilia on immunoglobulin-dependent activation. J Allergy Clin Immunol 1991;88:365-375.
10. WOERLY G, ROGER N, LOISEAU S, DOMBROWICZ D, CAPRON A, CAPRON M. Expression of CD28 and CD86 by human eosinophils and role in the secretion of type 1 cytokines (interleukin 2 and interferon gamma): inhibition by immunoglobulin A complexes. J Exp Med 1999;190:487-495.
11. ELSNER J, PETERING H, KLUTHE C et al. Eotaxin-2 activates chemotaxis-related events and release of reactive oxygen species via pertussis toxin-sensitive G proteins in human eosinophils. Eur J Immunol 1998;28:2152-2158.
12. GRANT SM, GOA KL, FITTON A, SORKIN EM. Ketotifen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders. Drugs 1990;40:412-448.
13. TINKELMAN DG, Moss BA, BUKANTZ SC et al. A multicenter trial of the prophylactic effect of ketotifen, theophylline, and placebo in atopic asthma. J Allergy Clin Immunol 1985;76:487-497.
14. BROBERGER U, GRA-LONNEVIG V, LILJA G, RYLANDER E. Ketotifen in pollen- induced asthma: a double blind placebo-controlled study. Clin Allergy 1986;16:119-127.
15. AGUILAR AJ. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate. Acta Ophthalmol Scand Suppl 2000;230:52-55.
16. MIKUNI IN, KOGURE F, UCHIDA Y et al. Clinical effect of ketotifen ophthalmic solution on allergic conjunctivitis and vernal conjunctivitis: multicentre doubleblind study in comparisons with disodium cromoglycate ophtalmic solution. Rinsho Hyoka 1989;17:275-297.
17. CHURCH MK, GRADIDGE CF. Inhibition of histamine release from human lung in vitro by antihistamine and related drugs. Br J of Pharmacol 1980;69:663-667.
18. ABE M, KUROSAWA M, IGARASHI Y, ISHIKAWA O, MIYACHI Y. Influence of IgE-mediated activation of cultured human mast cells on proliferation and type I collagen production by human dermal fibroblasts. J Allergy Clin Immunol 2000;106:S72-S77.
19. SAN JAR S, AOKI S, BOUBEKEUR K et al. Eosinophil accumulation in pulmonary airways of guinea-pigs induced by exposure to an aerosol of platelet-activating factor: effect of anti-asthma drugs. Br J Pharmacol 1990;99:267-272.
20. PODLESKI WK, PANASZEK BA, SCHMIDT JL, BURNS RB. Inhibition of eosinophils degranulation by ketotifen in a patient with milk allergy, manifested as bronchial asthma - an electron microscopic study. Agents Actions 1984;15:177-181.
21. BRANDT E, WOERLY G, YOUNES AB, LOISEAU S, CAPRON M. IL-4 production by human polymorphonuclear neutrophils. J Leukoc Biol 2000;68:125-130.
22. WALSH GM, DEWSON G, WARDLAW AJ, LEVI-SCHAER F, MOQBEL R. A comparative study of different methods for the assessment of apoptosis and necrosis in human eosinophils. J Immunol Methods 1998;217:153-163.
23. TRUNEH A, WHITE JR, PEARCE FL. Effect of ketotifen and oxatomide on histamine secretion from mast cells. Agents Actions 1982;12:206-209.
24. YANNI JM, STEPHENS DJ, MILLER ST et al. The in vitro and in vivo ocular pharmacology of olopatadine (AL4943A), an effective anti-allergic/antihistaminic agent. J Ocul Pharmacol Ther 1996;12:389-400.
25. BROIDE D, SRIRAMARAO P. Eosinophil trafficking to sites of allergic inflammation. Immunol Rev 2001;179:163-172.
26. ROTHENBERG ME, MISHRA A, BRANDT EB, HOGAN SP. Gastrointestinal eosinophils. Immunol Rev 2001;179:139-155.
27. HAMELMANN E, GELFAND EW. IL-5-induced airway eosinophilia - the key to asthma? Immunol Rev 2001;179:182-191.
28. FOSTER PS, MOULD AW, YANG M et al. Elemental signals regulating eosinophil accumulation in the lung. Immunol Rev 2001;179:173-181.
29. LEPREVOST C, CAPRON M, DE Vos C, TOMASSINI M, CAPRON A. Inhibition of eosinophil chemotaxis by a new antiallergic compound (cetirizine). Int Arch Allergy Appl Immunol 1988;87:9-13.
30. NABE M, MIYAGAWA H, AGRAWAL DK, SUGIYAMA H, TOWNLEY RG. The effect of ketotifen on eosinophils as measured at LTC4 release and by chemotaxis. Allergy Proc 1991;12:267-271.
31. FUKAGAWA K, NAKAJIMA T, TSUBOTA K, SHIMMURA S, SAITO H, HIRAI K. Presence of eotaxin in tears of patients with atopic keratoconjunctivitis with severe corneal damage. J Allergy Clin Immunol 1999;103:1220-1221.
32. UCHIO E, ONO SY, IKEZAWA Z, OHNO S. Tear levels of interferon-gamma, interleukin (IL)-2, IL-4 and IL-5 in patients with vernal keratoconjunctivitis, atopic keratoconjunctivitis and allergic conjunctivitis. Clin Exp Allergy 2000;30:103-109.
33. HOSHINO M, NAKAMURA Y, SHIN Z, FUKUSHIMA Y. Effects of ketotifen on symptoms and on bronchial mucosa in patients with atopic asthma. Allergy 1997;52:814-820.
34. MOTEGI Y, KITA H. Interaction with secretory component stimulates effector functions of human eosinophils but not of neutrophils. J Immunol 1998;161:4340-4346.
35. NONAKA M, NONAKA R, WOOLLEY K et al. Distinct immunohistochemical localization of IL-4 in human inflamed airway tissues. IL-4 is localized to eosinophils in vivo and is released by peripheral blood eosinophils. J Immunol 1995;155:3234-3244.
36. DUBUCQUOl S, DESREUMAUX P, JANIN A et al. Interleukin 5 synthesis by eosinophils: association with granules and immunoglobulin-dependent secretion. J Exp Med 1994;179:703-708.
37. KAYABA H, DOMBROWICZ D, WOERLY G, PAPIN JP, LOISEAU S, CAPRON M. Human eosinophils and human high affinity IgE receptor transgenic mouse eosinophils express low levels of high affinity IgE receptor, but release IL-10 upon receptor activation. J Immunol 2001;167:995-1003.
38. EZEAMUZIE CI, AL-HAGE M. Effects of some anti-asthma drugs on human eosinophil superoxide anions release and degranulation. Int Arch Allergy Immunol 1998;115:162-168.
39. CUI CH, HONDA K, SAITO N et al. Effect of roxithromycin on eotaxin-primed reactive oxygen species from eosinophils. Int Arch Allergy Immunol 2001;125:38-41.
40. OKAYAMA Y, BENYON RC, LOWMAN MA, CHURCH MK. In vitro effects of HI-anti-histamines on histamine and PGD2 release from mast cells of human lung, tonsil, and skin. Allergy 1994;49:246-253.
41. OKAYAMA Y, CHURCH MK. Comparison of the modulatory effect of ketotifen, sodium cromoglycate, procaterol and salbutamol in human skin, lung and tonsil mast cells. Int Arch Allergy Immunol 1992;97:216-225.
42. SUGIMOTO Y, TARUMI T, ZHAO QE, FUJII Y, KAMEI C. Effects of antiallergic drugs on histamine release from rat peritoneal mast cells induced by bradykinin. Methods Find Exp Clin Pharmacol 1998;20:457-462.
43. KISHIMOTO T, SATO T, ONO T, TAKAHASHI K, KIMURA I. Effect of ketotifen on the reactivity of eosinophils with the incubation of anti-IgG. Br J Clin Pract 1990;44:226-230.
44. HINGORANI M, CALDER V, JOLLY G, BUGKLEY RJ, LIGHTMAN SL. Eosinophil surface antigen expression and cytokine production vary in different ocular allergic diseases. J Allergy Clin Immunol 1998;102:821-830.
45. LACY P, MOQBEL R. Eosinophil cytokines. Chem Immunol 2000;76:134-155.
46. KAMINUMA O, OGAWA K, KIKKAWA H, KIKUCHI M, NAITO K, IKEZAWA K. A novel anti-allergic drug, betotastine besilate, suppresses interleukin-5 production by human peripheral blood mononuclear cells. Biol Pharm Bull 1998;21:411-413.
47. SAITO H, YAMAMOTO N, TOMITA S et al. Effect of emedastine difumarate on CC chemokine-elicited eosinophil migration. Int Arch Allergy Immunol 2001;125:22-28.
48. FUKAGAWA K, OKADA N, FUJISHIMA H et al. CC-chemokine receptor 3: a possible target in treatment of allergy-related corneal ulcer. Invest Ophthalmol Vis Sci 2002;43:58-62.
49. ABU EL-ASRAR AM, STRUYF S, AL-KHARASHI SA, MISSOTTEN L, VAN DAMME I, GEBOES K. Chemokines in the limbal form of vernal keratoconjunctivitis. Br J Ophthalmol 2000;84:1360-1366.
50. KATO M, HATTORI T, TAKAHASHI M, YANAGITA N, NAKASHIMA I. Eosinophil cationic protein and prophylactic treatment in pollinosis in natural allergen provocation. Br J Clin Pract 1994;48:299-301.
51. KATO M, HATTORI T, KITAMURA M, BEPPU R, YANAGITA N, NAKASHIMA I. Major basic protein and topical administration of ketotifen in pollinosis under natural allergen provocation. ORL J Otorhinolaryngol Relat Spec 1995;57:269-272.
52. LEONARDI A, BORGHESAN F, AVARELLO A, PLEBANI M, SECCHI AG. Effect of lodoxamide and disodium cromoglycate on tear eosinophil cationic protein in vernal keratoconjunctivitis. Br J Ophthalmol 1997;81:23-26.